Triple-negative breast cancer (TNBC; without ER, PR and HER2 expression) represents nearly 15% (Table 1) of BCs and have short disease-specific survival and poor prognosis [5, 13]. Here, ERBB2 is linked to triple-negative breast carcinoma.